高级搜索

131I 标记抗CD20 单克隆抗体在荷瘤裸鼠体内的放射免疫显像

左 强, 张军一, 陈锦章, 罗荣城

左 强, 张军一, 陈锦章, 罗荣城. 131I 标记抗CD20 单克隆抗体在荷瘤裸鼠体内的放射免疫显像[J]. 肿瘤防治研究, 2007, 34(07): 473-476. DOI: 10.3971/j.issn.1000-8578.1301
引用本文: 左 强, 张军一, 陈锦章, 罗荣城. 131I 标记抗CD20 单克隆抗体在荷瘤裸鼠体内的放射免疫显像[J]. 肿瘤防治研究, 2007, 34(07): 473-476. DOI: 10.3971/j.issn.1000-8578.1301
ZUO Qiang, ZHANG Jun-yi, CHEN Jin-zhang, LUO Rong-cheng. Radioimmunoimaging of Anti-CD20 Monoclonal Antibody Labeled with 131I in Nude Mice Xenografted with Raji Cells Tumor in Vivo[J]. Cancer Research on Prevention and Treatment, 2007, 34(07): 473-476. DOI: 10.3971/j.issn.1000-8578.1301
Citation: ZUO Qiang, ZHANG Jun-yi, CHEN Jin-zhang, LUO Rong-cheng. Radioimmunoimaging of Anti-CD20 Monoclonal Antibody Labeled with 131I in Nude Mice Xenografted with Raji Cells Tumor in Vivo[J]. Cancer Research on Prevention and Treatment, 2007, 34(07): 473-476. DOI: 10.3971/j.issn.1000-8578.1301

131I 标记抗CD20 单克隆抗体在荷瘤裸鼠体内的放射免疫显像

详细信息
    通讯作者:

    罗荣城

  • 中图分类号: R817. 4 ; R733

Radioimmunoimaging of Anti-CD20 Monoclonal Antibody Labeled with 131I in Nude Mice Xenografted with Raji Cells Tumor in Vivo

More Information
    Corresponding author:

    LUO Rong-cheng

  • 摘要: 目的 探讨131I-anti-CD20McAb经瘤内注射后在荷人Burkitt's淋巴瘤细胞系Raji细胞移植瘤裸鼠体内的放射免疫显像。方法 131I标记物的标记采用IODO-GEN碘化标记;注射标记物后第1、3、7、15天将荷瘤裸鼠SPECT显像后活杀,定标器测量并计算瘤、血等12种器官或组织的%ID/g值,根据MIRD委员会推荐的公式计算肿瘤累积吸收剂量。结果 131I-anti-CD20McAb瘤内注射组的SPECT显像结果优于腹腔注射组和131I-IgG瘤内注射组,该组肿瘤%ID/g值在给药后第1、3和7天分别为后两组的1.4~17倍和1.7~3.7倍,肿瘤累及吸收剂量在给药后第3、7和15天分别为后两组的1.5~2.5倍和6.0~12.6倍。结论 131I-anti—CD20McAb经瘤内途径给药可以使肿瘤获得最高的放射性药物摄取率.为下一步运用该途径进行放射免疫治疗提供了实验依据。

     

    Abstract: Objective  To exploit the radioimmunoimaging of iodine-131 labeled anti-CD20McAb with intratumor injection( IT) in nude mice xenografted with raji cells tumor. Methods  Iodine-131 labeled anti-CD20McAb by iodogen method. The mice were imaged by SPECT and killed following on one、three、seven and fifteen day after injection. The injected dose/ gramtissue ( %ID/ g) percentages of different organs, including tumor, blood, etal were measured by calibrator and calculated. Dosimetry of cumulate absorption in tumor was performed using MIRD formula. Results  131I-anti-CD20McAb IT group showed clearer images in tumors than int raperitoneal injection ( IP) and 131I-IgGIT control groups. The %ID/ g in tumor in 131I-anti-CD20McAb IT group were 1. 4~17 fold higher than that in IP group and 1. 7~3. 7 in IgG IT group, and the cumulate absorbed dose were 6. 0~12. 6 and 1. 5~2. 5 fold higher than the other two groups. Conclusion  Tumor could have the highest absorbed radioactive drugs with intratumor injection of 131I-anti-CD20McAb, which offered the experimental evidence for the next radioimmunotherapy.

     

计量
  • 文章访问数:  2440
  • HTML全文浏览量:  16
  • PDF下载量:  883
  • 被引次数: 0
出版历程
  • 收稿日期:  2006-06-25
  • 修回日期:  2006-09-10
  • 刊出日期:  2007-07-04

目录

    /

    返回文章
    返回
    x 关闭 永久关闭